How would you manage subsequent treatment for a patient with metastatic ER+HER2- breast cancer that develops pneumonitis on a CDK4/6 inhibitor but had an excellent response to therapy?
Would you change to a different CDK4/6 inhibitor or avoid the entire class of drugs?
Answer from: Medical Oncologist at Academic Institution
Decisions like this should always be made with subspecialty input from a pulmonologist, and account for the degree and severity of the pneumonitis. The development of pneumonitis may well be a class effect (indeed, pneumonitis was observed in clinical trials of all three approved CDK4/6 inhibitors) ...
I will be reluctant to switch or re-challenge.